The overexpression of P21-activated kinase 5 (PAK5) promotes paclitaxel-chemoresistance of epithelial ovarian cancer

Molecular and Cellular Biochemistry

Volumn 383, Issue 1-2, 2013, Pages 191-199

  Li, Diyou ^a   Yao, Xiaohong ^a   Zhang, Ping ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cancer progression and migration; Epithelial ovarian cancer; Paclitaxel resistance; PAK5

Indexed keywords

CARBOPLATIN; COMPLEMENTARY DNA; P21 ACTIVATED KINASE; P21 ACTIVATED KINASE 5; PACLITAXEL; PROPIDIUM IODIDE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE SILENCING; GYNECOLOGIC CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL MEMBRANE; CELL PROLIFERATION; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; P21-ACTIVATED KINASES; PACLITAXEL; RNA INTERFERENCE;

EID: 84885429538     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1767-7     Document Type: Article

References (25)

1. Cotteret S, Jaffer ZM, Beeser A, Chernoff J (2003) p21-Activated kinase 5 (Pak5) localizes to mitochondria and inhibits apoptosis by phosphorylating BAD. Mol Cell Biol 23(16):5526-5539
2. Wang X, Gong W, Qing H, Geng Y, Wang X, Zhang Y et al (2010) p21-activated kinase 5 inhibits camptothecin-induced apoptosis in colorectal carcinoma cells. Tumour Biol 31(6):575-582
3. Cau J, Faure S, Comps M, Delsert C, Morin N (2001) A novel p21-activated kinase binds the actin and microtubule networks and induces microtubule stabilization. J Cell Biol 155(6):1029-1042
4. Nguyen TV, Galvan V, Huang W, Banwait S, Tang H, Zhang J et al (2008) Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664. J Neurochem 104(4):1065-1080
5. Eswaran J, Lee WH, Debreczeni JE, Filippakopoulos P, Turnbull A, Fedorov O et al (2007) Crystal structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 15(2):201-213
6. Dan I, Watanabe NM, Kusumi A (2001) The Ste20 group kinases as regulators of MAP kinase cascades. Trends Cell Biol 11(5):220-230
7. Cotteret S, Chernoff J (2006) Nucleocytoplasmic shuttling of Pak5 regulates its antiapoptotic properties. Mol Cell Biol 26(8):3215-3230
8. Dan C, Nath N, Liberto M, Minden A (2002) PAK5, a new brain-specific kinase, promotes neurite outgrowth in N1E-115 cells. Mol Cell Biol 22(2):567-577
9. Salminen A, Suuronen T, Kaarniranta K (2008) ROCK, PAK, and Toll of synapses in Alzheimer's disease. Biochem Biophys Res Commun 371(4):587-590
10. Timm T, Matenia D, Li XY, Griesshaber B, Mandelkow EM (2006) Signaling from MARK to tau: regulation, cytoskeletal crosstalk, and pathological phosphorylation. Neurodegener Dis 3(4-5):207-217
11. Permuth-Wey J, Sellers TA (2009) Epidemiology of ovarian cancer. Methods Mol Biol 472:413-437
12. Vasey PA (2003) Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br J Cancer 89(Suppl 3):S23-S28
13. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93(9):2325-2327
14. Detre S, Saclani Jotti G, Dowsett M (1995) A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 48(9):876-878
15. Lopez-Gasco P, Iglesias I, Benedi J, Lozano R, Blanco MD (2012) Characterization and in vitro bioactivity evaluation of paclitaxel-loaded polyester nanoparticles. Anticancer Drugs 23(9):947-958
16. Balasenthil S, Sahin AA, Barnes CJ, Wang RA, Pestell RG, Vadlamudi RK et al (2004) p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 279(2):1422-1428
17. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G (2006) Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients. J Natl Cancer Inst 98(10):671-680
18. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO et al (2004) Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 10(10):3448-3456
19. Wells CM, Abo A, Ridley AJ (2002) PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J Cell Sci 115(Pt 20):3947-3956
20. Matenia D, Griesshaber B, Li XY, Thiessen A, Johne C, Jiao J et al (2005) PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. Mol Biol Cell 16(9):4410-4422
21. Pandey A, Dan I, Kristiansen TZ, Watanabe NM, Voldby J, Kajikawa E et al (2002) Cloning and characterization of PAK5, a novel member of mammalian p21-activated kinase-II subfamily that is predominantly expressed in brain. Oncogene 21(24):3939-3948
22. Giroux V, Iovanna JL, Garcia S, Dagorn JC (2009) Combined inhibition of PAK7, MAP3K7 and CK2alpha kinases inhibits the growth of MiaPaCa2 pancreatic cancer cell xenografts. Cancer Gene Ther 16(9):731-740
23. Brigulova K, Cervinka M, Tosner J, Sedlakova I (2010) Chemoresistance testing of human ovarian cancer cells and its in vitro model. Toxicol In Vitro 24(8):2108-2115
24. Salom E, Penalver M, Homesley H, Burrell M, Garrett A, Presant CA et al (2012) Correlation of pretreatment drug induced apoptosis in ovarian cancer cells with patient survival and clinical response. J Transl Med 10(1):162
25. Wu X, Carr HS, Dan I, Ruvolo PP, Frost JA (2008) p21 activated kinase 5 activates Raf-1 and targets it to mitochondria. J Cell Biochem 105(1):167-175